Sat, Oct 25, 2014, 11:32 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • terry_insm terry_insm Jul 15, 2013 11:05 AM Flag

    Arikace competition - Novartis the EU and NICE

    Insmed Shareholders should understand the competition and where Arikace may position themselves.
    Novartis TIP (pod inhaler) received a recommendation from NICE. If you listen to the JPM conferenece NICE is mentioned.
    Of course TIP is years ahead and Novartis is strongly positioning themselves in both the U.S(2013) and EU (2011). Thanks to glises58g for the refrigeration is needed, req for Arikace and other variations
    NICE recommended TOBI® Podhaler® (tobramycin inhalation powder) as a cost-effective therapy...
    Can Insmed compete? Wil Lewis did mention the strong need for Arikace to lower their cost in order to be competitive
    The NICE appraisal committee concluded that tobramycin dry powder provides a cost benefit compared to existing nebulized alternatives Dr Diana Bilton, Consultant Respiratory Physician, Royal Brompton Hospital, London said, "Our experience is that patients really benefit from this antibiotic inhaler in terms of a reduction in treatment burden and being able to get on with life instead of spending time on a nebulizer. The Committee also concluded that in clinical practice people with CF may benefit from the speed and convenience of this dry powder inhaler.The Podhaler® is a novel drug delivery system with patented technology that delivers tobramycin inhalation powder via a hand-held, portable inhaler2,3. ****Trials have shown that those patients using the drug-delivery device completed their treatment in just five to six minutes, twice a day***** with similar efficacy to tobramycin nebulizer solution.
    Good Luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Arikace competition - Novartis the EU and NICE.

      Insmed Shareholders should understand the competition and where Arikace may position themselves.
      Novartis TIP (pod inhaler) received a recommendation from NICE. If you listen to the JPM conferenece NICE is mentioned.
      Of course TIP is years ahead and Novartis is strongly positioning themselves in both the U.S(2013) and EU (2011). Thanks to glises58g for the refrigeration is needed, req for Arikace and other variations
      NICE recommended TOBI® Podhaler® (tobramycin inhalation powder) as a cost-effective therapy...
      Can Insmed compete? Wil Lewis did mention the strong need for Arikace to lower their cost in order to be competitive
      The NICE appraisal committee concluded that tobramycin dry powder provides a cost benefit compared to existing nebulized alternatives Dr Diana Bilton, Consultant Respiratory Physician, Royal Brompton Hospital, London said, "Our experience is that patients really benefit from this antibiotic inhaler in terms of a reduction in treatment burden and being able to get on with life instead of spending time on a nebulizer. The Committee also concluded that in clinical practice people with CF may benefit from the speed and convenience of this dry powder inhaler.The Podhaler® is a novel drug delivery system with patented technology that delivers tobramycin inhalation powder via a hand-held, portable inhaler2,3. ****Trials have shown that those patients using the drug-delivery device completed their treatment in just five to six minutes, twice a day***** with similar efficacy to tobramycin nebulizer solution.
      Good Luck

      • 1 Reply to insm_truth_teller
      • Arikace competition - Novartis the EU and NICE.
        Insmed Shareholders should understand the competition and where Arikace may position themselves.
        Novartis TIP (pod inhaler) received a recommendation from NICE. If you listen to the JPM conferenece NICE is mentioned.
        Of course TIP is years ahead and Novartis is strongly positioning themselves in both the U.S(2013) and EU (2011). Thanks to glises58g for the refrigeration is needed, req for Arikace and other variations
        NICE recommended TOBI® Podhaler® (tobramycin inhalation powder) as a cost-effective therapy...
        Can Insmed compete? Wil Lewis did mention the strong need for Arikace to lower their cost in order to be competitive
        The NICE appraisal committee concluded that tobramycin dry powder provides a cost benefit compared to existing nebulized alternatives Dr Diana Bilton, Consultant Respiratory Physician, Royal Brompton Hospital, London said, "Our experience is that patients really benefit from this antibiotic inhaler in terms of a reduction in treatment burden and being able to get on with life instead of spending time on a nebulizer. The Committee also concluded that in clinical practice people with CF may benefit from the speed and convenience of this dry powder inhaler.The Podhaler® is a novel drug delivery system with patented technology that delivers tobramycin inhalation powder via a hand-held, portable inhaler2,3. ****Trials have shown that those patients using the drug-delivery device completed their treatment in just five to six minutes, twice a day***** with similar efficacy to tobramycin nebulizer solution.
        Good Luck

    • I do think that there is a general reluctance amoung doctors to prescribe inhalation of a powder, if there is an alternative liquid (despite what the safety results are)....

    • NICEly done.

    • lux19insm@rocketmail.com lux19insm Jul 15, 2013 12:04 PM Flag

      this is odd - fud agreeing with terry - it's like dogs and cats playing together

      • 1 Reply to lux19insm
      • Credit where credit's due - Terry made an important point.

        TIP displaced traditional TOBI (for those who can tolerate an inhaled powder) because it's not only portable but also less time-consuming.

        Arikace will displace TIP because it's also portable, once-daily instead of twice-daily, delivers a sustained improvement in breathing over multiple cycles of therapy, and doesn't have the unpleasant side effects associated with an inhaled powder.

    • Good point Terry -

      "Dr Diana Bilton, Consultant Respiratory Physician, Royal Brompton Hospital, London said, "Our experience is that patients really benefit from this antibiotic inhaler in terms of a reduction in treatment burden and being able to get on with life instead of spending time on a nebulizer."

      Dr Bitlon is eminently qualified to predict the improvement in compliance with a more patient-friendly therapy.

      Wasn't it Dr. Bilton who, during the call following the release of the Phase III results, predicted that her patients would be lining up for a once-daily therapy?

      And Arikace is not only twice as convenient as TIP -

      1. The side effects from TIP were such that 27% of those taking TIP dropped out of the clinical trial.

      2. In one of the clinical trials TIP failed to deliver significantly better efficacy than a PLACEBO.

      Arikace delivered an improvement in lung function throughout the course of a Phase II study spanning 72 weeks. No other inhaled antibiotic has ever generated data which even hinted at delivering a noticeable improvement beyond a month or two.

      Once somebody with CF needs antibiotics he/she will need them for life. Arikace is now the only real choice as the central therapy.

      The others will fight it out for use during the Arikace off-therapy phases of the regimen.

 
INSM
14.27-0.06(-0.42%)Oct 24 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.